260422_웨비나 2차 [오가나 원장님]

Scientific concepts / discoveries / nature-phenomena described

• Liquid formulation of PCL (Polycaprolactone)

  • Described as a liquid-type PCL, differing from traditional powder/particle-based biostimulators.
  • Key property: after injection, it forms a reticular (mesh-like) scaffold rather than hard nodules.

• Reticular scaffold → controlled diffusion and tissue support

  • The liquid is compared to dropping “blue ink” into water, then diffusing evenly.
  • Claims include even spread through the epidermis, dermis, and into the dermal adipose layer, enabling a layer-by-layer strategy.
  • Because it forms a fine, sponge-like network:
    • it supports tissue structure rather than only adding volume,
    • it reduces the risk of over-correction / overgrowth of nodules.

• Fibroblast stimulation → collagen biosynthesis

  • Mechanism described: the mesh/thread-like scaffold stimulates fibroblasts, leading to a delayed collagen response.
  • Reported outcomes (from a cited clinical trial mentioned in the subtitles):
    • Dermal thickness increased >30%
    • Collagen type expression increased >4×
    • Collagen density increased >60%

• Comparison to particle-based biosimulators (e.g., “rice grain in water” analogy)

  • Particle/powder products: particles swell and form more rigid collagen around them, which the summary associates with large nodules and limited diffusion.
  • Risks mentioned:
    • over-correction, requiring nodule removal
    • vascular accident–type side effects (as stated)

• Hyaluronic acid (HA) synergy via scaffold trapping

  • The video claims HA “trapped” within the reticular scaffold leads to longer-lasting hydration than conventional HA injections, which dissolve quickly.
  • Suggested mixing ratios are referenced (commonly 1:1 or other ratios).

• Multi-needle injector (DermaShine / “Loop” technique)

  • Used to apply the treatment at controlled depths targeting different layers:
    • Surface layer: easier/more uniform, reportedly less painful
    • Middle layer: more painful; described as longer-lasting
    • Deep layer: reported to provide lifting by vector-direction targeting
  • Reported advantages: more even delivery than by hand; fast application (about ~5 minutes).

• Layered, depth-adjusted treatment strategy (methodology)

  • Injector depth adjustments mentioned:
    • ~1 mm baseline for shallow/surface approach
    • reduce by ~0.5 mm to accommodate pain sensitivity
    • increase up to ~1.2 mm for a longer-lasting effect
  • Approximate dosing mentioned for face surface treatment: ~2 cc to 2.5 cc (with dilution considerations).

• Thermal stimulation / Needle RF synergy (RF + liquid PCL ring)

  • For a combined approach:
    • RF provides physical + thermal stimulation, promoting recovery and collagen regeneration.
    • The video claims combining RF with the liquid PCL scaffold may also induce chemical reactions, yielding “physical + chemical” synergy (as stated).

• Drug-mixing / dilution concepts for controlling viscosity and flow

  • Because it is liquid PCL, the video notes potential excess flow or loss.
  • Proposed adjustment: mix with hyaluronic acid formulations to tune viscosity (ratios like 1:1 or 3:7 referenced).

• Clinical outcome examples (reported phenomena)

  • Improvements shown/claimed in the subtitles include:
    • lifting (jawline/under-eye/cheek contour improvement)
    • tear trough, nasolabial fold, marionette line improvement
    • reduced fine lines
    • skin tone brightening
    • improvement of inflammatory lesions (via barrier improvement)
    • reduction of dark circles under eyes (with caution about bruising)

---

Methodology / procedure steps (as described)

• Core product approach

  • Dilute/open the liquid PCL ring, then mix thoroughly.

• Injection delivery options

  • Surface layer strategy (recommended for dryness / sensitive skin)

    • Use multi-needle injector (DermaShine Pro).
    • Inject at shallow depth (around ~1 mm, adjusted for pain tolerance).
    • Target: internal dryness, sensitive skin, barrier weakness.
    • Described as possible once or 3 times at intervals (interval length is ambiguous in the subtitles; described as “1”).
    • Reported as low pain and uniform spread; minimal bruising.

  • Middle layer strategy (strengthen dermis/collagen deeper than surface)

    • Use manual injection (subtitles indicate it hurts).
    • Mentions risk of wheals/clumping, resolving within 1–2 hours.

  • Deep layer strategy (lifting effect via vector targeting)

    • Aim at ~45° below the eyes / below temples for cheek/temple targeting.
    • Use two holes on each side to cover directions (top/bottom/sides/under-eye).
    • Example needle length mentioned: 7 cm.
    • Dilution preference referenced like 1:4.
    • Mixing includes lidocaine + epinephrine to reduce bruising (as stated).

• Combination therapy

  • Mix/combination with HA products (to extend hydration effect).
  • Optionally combine with stem cells/plasma (described as helping retain/sustain effects).
  • Optionally combine with Needle RF for thermal/physical stimulation; claimed to enhance collagen and barrier improvements.

---

Advantages / disadvantages and safety notes mentioned

• Advantages of liquid PCL ring vs particle/powder

  • More predictable and even diffusion
  • Lower risk of over-correction/nodule formation
  • Scaffold supports tissue structure (not just volume)
  • Suitable for layer-by-layer targeting with synergy possibilities (especially with HA)

• Common/temporary side effects

  • Temporary swelling/edema
    • described as having two peaks:
      • immediately after, up to ~2 days
      • brief recurrence in the first week
  • Bruising
    • Subtitles say multi-needle may reduce bruising; deeper layers may last longer.
    • Under-eye bruising described as potentially lasting ~3–6 months.
    • Also mentioned: bruising can occur if the patient injures themselves after the procedure.
  • Allergic reactions
    • reported as <1% in the subtitles
    • symptoms like itching, redness, “rash/dermatitis”
    • managed with antihistamines or steroids
  • Rare severe facial deformity
    • ~1–2 per 1,000
    • manage with medications and wait ~4–6 months before next procedure

• Precautions for allergy/swelling

  • Preemptive medication described:
    • steroids or antihistamines (timing sometimes “immediately after” or “before”)
  • If an adverse reaction recurs, subtitles recommend:
    • waiting about ~4 months before retesting/repeating
    • possibly switching products if the allergy is to other ingredients

---

Researchers / sources featured (named in subtitles)

• Dr. Ogana (오가나 원장님 / Oganacell Dermatology) — representative director (speaker)
• Oganacell Dermatology (Cheongdam branch mentioned)